Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy

Jaecheol Lee,Vittavat Termglinchan,Sebastian Diecke,Ilanit Itzhaki,Chi Keung Lam,Priyanka Garg,Edward Lau,Matthew Greenhaw,Timon Seeger,Haodi Wu,Joe Z. Zhang,Xingqi Chen,Isaac Perea Gil,Mohamed Ameen,Karim Sallam,June-Wha Rhee,Jared M. Churko,Rinkal Chaudhary,Tony Chour,Paul J. Wang,Michael P. Snyder,Howard Y. Chang,Ioannis Karakikes,Joseph C. Wu
DOI: https://doi.org/10.1038/s41586-019-1406-x
IF: 64.8
2019-07-17
Nature
Abstract:Lamin A/C (<i>LMNA</i>) is one of the most frequently mutated genes associated with dilated cardiomyopathy (DCM). DCM related to mutations in <i>LMNA</i> is a common inherited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias. Here we modelled the LMNA-related DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhythmias at the single-cell level. Mechanistically, we show that the platelet-derived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs compared to isogenic control iPSC-CMs. Conversely, pharmacological and molecular inhibition of the PDGF signalling pathway ameliorated the arrhythmic phenotypes of mutant iPSC-CMs in vitro. Taken together, our findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of LMNA-related DCM and point to PDGF receptor-β (PDGFRB) as a potential therapeutic target.
multidisciplinary sciences
What problem does this paper attempt to address?